More Medicines

By 't Hoen, Ellen; von Schoen-Angerer, Tido | The World Today, February 2009 | Go to article overview

More Medicines


't Hoen, Ellen, von Schoen-Angerer, Tido, The World Today


Around three million people living with AIDS indeveloping countries have access to treatment, a ten-fold increase in just a few years. A key factor in this dramatic achievement was the availability of low-cost drugs produced in India, the pharmacy of the developing world. Companies there could produce AIDS drugs generically because the country did not grant medicine patents until 2005. However, this is now changing. India has begun granting patents on medicines to meet its obligations under the 1994 World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The prices of newer essential medicines are likely to rise, threatening the viability of many AIDS treatment programmes - and access to medicines more broadly. An international patent pool for essential medicines could help address this looming crisis.

tHE IDEA BEHIND A PATENT POOL IS THAT different patent-holders, such as companies, universities and research institutes, would make their patents available to others on a non-exclusive basis through the pool. Generic manufacturers could then access patents in the pool to producemedicines, and tomake further improvements to them. Patent holders would receive royalties fromthose using the patents.

Recently UNITAID, a new multilateral financing mechanism for the purchase of medicines, has taken the initiative to develop an international medicines patent pool through which medicine patents could be made available to produce generic versions of AIDS drugs. It could also ease the development of adapted formulations such as three-in-one combination pills andmedicines for children.

Any qualified company that wanted to use the inventions could get a licence from the pool. The UNITAID pool would be voluntary, and the resulting medicines would be available only in developing countries.

Under the scheme the products cannot 'leak' into western markets because they are produced by a third company under its own name and possibly brand. Such a company would have to ask for marketing authorisation in countries where the products are under patent and where the pool licenses would not be valid. If they did this they would immediately be confronted with legal action by the patent holder. This is why today, for example, you do not see Indian generic antiretrovirals in Europe or the US. The same would be the case for the generics produced under pool licences.

WHY IS A POOL NECESSARY?

Many patients need access to newer AIDSmedicines, either because they are safer treatment options, or because drug resistance renders older drugs less effective. However, newer drugs are widely patented, including in key producing countries such as India.

As a result, the prices of AIDS medicines are on the rise again. At $600-1000 per patient per year, using originator products, the improved first-line treatment recommended by the World Health Organization (WHO) costs six to ten times as much as the currently most widely used regimen. Furthermore, children's needs continue to be overlooked: of the 22 antiretrovirals available, nine are not approved for paediatric use and seventeen are not available in paediatric formulations.

The high cost of newerAIDS drugs has led to trade disputes when countries have decided to set patents aside through compulsory licensing to access lower cost generic drugs. High profile political conflicts over intellectual property rights involving the United States, the European Union and patent holding pharmaceutical companies on one side, and Thailand, Brazil, SouthAfrica or other developing countries on the other, have drawn attention to this issue in recent years.

The patent pool would provide a more predictable way of managing medicines-related intellectual property by easing the licensing process to achieve two main objectives: to lower the price ofmedicines by encouraging competitive production, and to stimulate development of combination pills that can be more easily taken by the patient. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

More Medicines
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.